Scarica l'app Stockscreener
3.18
0.31%
-0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.19
Aprire:
$3.18
Volume 24 ore:
58.43M
Relative Volume:
3.90
Capitalizzazione di mercato:
$819.46M
Reddito:
$418.24M
Utile/perdita netta:
$-7.42M
Rapporto P/E:
-30.75
EPS:
-0.1034
Flusso di cassa netto:
$-10.88M
1 W Prestazione:
+0.63%
1M Prestazione:
+1.27%
6M Prestazione:
-18.04%
1 anno Prestazione:
+156.45%
Intervallo 1D:
$3.18
$3.19
Intervallo di 1 settimana:
$3.15
$3.19
Portata 52W:
$1.10
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.18 | 819.46M | 418.24M | -7.42M | -10.88M | -0.1034 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger - Yahoo Finance
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Esperion Therapeutics Stockholders Approve Merger with Essence Parent Inc. – Key SEC 8-K Filing Details - Minichart
Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote - Stock Titan
Esperion Therapeutics stock leans on its cholesterol portfolio. - ad-hoc-news.de
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics (ESPR) AGM 2026 Summary - Quartr
ESPREsperion Therapeutics Inc Volatility & Greeks - Finviz
Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings - Moomoo
Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth - AD HOC NEWS
ESPR Stock Price, Quote & Chart - ChartMill
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
ESPR News | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
Esperion Therapeutics Company Profile & Introduction - Moomoo
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR - TradingView
Price to earnings forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR - TradingView
Esperion Therapeutics, Inc. Actuals & Estimates (NASDAQ:ESPR) - TradingView
Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET) - TradingView
ESPR Forecast — Price Target — Prediction for 2027 - TradingView
Esperion Therapeutics Inc (ESPR) Institutional Confidence - TradingKey
Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades - Yahoo Finance
Esperion (NASDAQ: ESPR) CLO trims 11,824 shares to pay RSU taxes - Stock Titan
Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M - Stock Titan
Esperion (NASDAQ: ESPR) CFO sells shares to pay taxes on vested RSUs - Stock Titan
Esperion (NASDAQ: ESPR) details Corstasis acquisition cost, debt and royalty financing - Stock Titan
Esperion Therapeutics (ESPR) Proxy filing Summary - Quartr
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Inve - The National Law Review
ESPR insider sale notice: 53,588 shares tied to vesting (ESPR) - Stock Titan
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - Business Wire
Benjamin Halladay to sell 10,773 ESPR shares after vesting (ESPR) - Stock Titan
ESPR (NASDAQ: ESPR) files Form 144 to sell 11,824 vested shares - Stock Titan
Esperion Therapeutics Inc (ESPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Esperion Therapeutics Inc (ESPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Esperion Therapeutics Inc (ESPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Esperion Therapeutics Inc (ESPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Esperion Therapeutics Inc (ESPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Esperion Therapeutics Inc (ESPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Esperion (NASDAQ: ESPR) gains HSR clearance ahead merger vote - Stock Titan
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Esperion Therapeutics Inc. (ESPR) News, Articles, Events & Latest Updates - Stocktwits
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.42%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):